Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01188499 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 study of Cancer, sponsored by TetraLogic Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
- 7
- Study locations
NCT01188499: Completed Phase 1 study of Cancer, sponsored by TetraLogic Pharmaceuticals.
NCT01188499 is a Phase 1 study of Cancer that has completed, run by TetraLogic Pharmaceuticals. The registered enrollment target is 176 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01188499, a Phase 1 study of Cancer, has completed, sponsored by TetraLogic Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a dose escalation safety study of birinapant (TL32711) in combination with chemotherapy in subjects with advanced or metastatic solid tumors.
Primary Outcome
Number of subjects with adverse events as a measure of safety and tolerability including changes in vital signs, electrocardiograms (ECGs), safety and laboratory parameters
Conditions Studied
Interventions
- DRUG Birinapant
Study Locations (7)
Pennsylvania
- University of Pennsylvania Abramson Cancer Center - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Texas
- Mary Crowley Cancer Research Center - Dallas
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Florida
- Holy Cross Hospital - Fort Lauderdale
Michigan
- Barbara Ann Karmanos Cancer Center - Detroit
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
What the finished NCT01188499 record still lists
NCT01188499 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Birinapant is the first listed.
NCT01188499 lists 7 locations in 5 states (Pennsylvania, Texas, Florida).
Frequently Asked Questions
What is clinical trial NCT01188499 about?
NCT01188499 is a clinical study titled "Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors". This is a dose escalation safety study of birinapant (TL32711) in combination with chemotherapy in subjects with advanced or metastatic solid tumors.
What is the current status of trial NCT01188499?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2010-10. Estimated completion is 2014-03.
What conditions does trial NCT01188499 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT01188499?
The interventions under investigation include: Birinapant (DRUG).
Who is sponsoring clinical trial NCT01188499?
This trial is sponsored by TetraLogic Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01188499 being conducted?
This trial has 7 study locations across Florida, Michigan, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01188499's enrollment target sits among peer trials
176 249th of 615 higher than 367 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia